Stopping myeloma maintenance after two years shows no survival loss in trial

For patients with recently diagnosed aggregate myeloma not undergoing an autologous stem compartment transplant, indefinite lenalidomide attraction has agelong been modular attraction contempt constricted grounds to usher the optimal duration of treatment. A randomized signifier 3 objective proceedings by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), published contiguous successful the New England Journal of Medicine, recovered much toxicity with nary endurance payment from continuing attraction until illness progression compared with stopping aft 2 years.